Drug Metabolism is the set of biochemical processes through which an organism chemically modifies drugs and other xenobiotic substances. Metabolism can alter a compound's activity, duration, distribution, toxicity and route of elimination and is therefore a central component of pharmacokinetics and clinical pharmacology. The liver is a major site of drug metabolism, but significant metabolism can also occur in the intestine, kidneys, lungs, blood and other tissues.
Metabolic reactions commonly increase polarity or otherwise transform lipophilic compounds into forms that can be excreted more readily, although metabolism does not always produce inactive or less toxic substances. Some drugs are administered as inactive or less active prodrugs that require metabolic conversion to generate their pharmacologically active forms. Conversely, metabolism can generate reactive or toxic intermediates. Drug metabolism is traditionally divided into Phase I reactions, which often involve oxidation, reduction or hydrolysis, and Phase II reactions, which commonly involve conjugation with endogenous molecules. These categories are useful but do not encompass every metabolic pathway or imply a rigid sequence.
Phase I metabolism commonly involves cytochrome P450 enzymes, flavin containing monooxygenases, esterases, amidases and other enzyme systems. Cytochrome P450 enzymes are particularly important because they catalyse oxidation of many chemically diverse drugs. Major human CYP enzymes involved in drug metabolism include CYP3A4 and CYP3A5, CYP2D6, CYP2C9, CYP2C19 and CYP1A2, although their contributions differ among drugs and individuals. Oxidation can introduce or expose functional groups and may produce metabolites that are more polar than the parent drug.
Reduction and hydrolysis provide alternative Phase I pathways, particularly for compounds containing appropriate chemical groups. Phase I metabolism can terminate activity, reduce activity, leave activity relatively unchanged or generate a metabolite with greater activity or toxicity. The chemical structure of the drug strongly influences which enzymes can act upon it, while enzyme expression varies according to genetics, age, disease, diet, environmental exposures and other medicines.
Phase II metabolism generally involves conjugation of a drug or Phase I metabolite with an endogenous molecule, increasing hydrophilicity and facilitating elimination. Important conjugation pathways include glucuronidation, sulfation, acetylation, methylation, glutathione conjugation and amino acid conjugation. UDP glucuronosyltransferases catalyse glucuronidation reactions that are particularly important for many medicines and endogenous compounds. Glutathione conjugation can help detoxify electrophilic reactive metabolites by attaching them to the tripeptide glutathione, although depletion of glutathione can increase susceptibility to oxidative or chemical injury.
Acetylation capacity varies genetically for some pathways, producing differences between individuals in the rate at which particular drugs are metabolised. Conjugation does not invariably make every compound harmless, and some conjugated metabolites can have biological activity or undergo further transformation. Phase II processes are therefore best understood as part of an interconnected metabolic network rather than a universal final detoxification step.
Drug metabolism strongly influences oral bioavailability through first pass metabolism. After an orally administered drug is absorbed from the gastrointestinal tract, it may enter the portal circulation and pass through the intestinal wall and liver before reaching systemic circulation. Enzymatic metabolism during this passage can substantially reduce the amount of unchanged drug reaching the bloodstream. The extent of first pass extraction depends on intestinal and hepatic enzyme activity, transporter activity, hepatic blood flow and drug properties.
High first pass metabolism can make oral dosing less efficient and may contribute to substantial variability among patients. Other routes such as intravenous administration bypass gastrointestinal absorption and hepatic first pass extraction, while some routes can partially bypass these processes. Understanding first pass metabolism is therefore essential when comparing oral and systemic dosing and when designing formulations intended to achieve predictable exposure.
Drug metabolism is a major source of drug interactions. Enzyme inhibition can reduce metabolic clearance of a substrate drug and increase its concentration, potentially increasing adverse effects. Enzyme induction can increase metabolic capacity and lower concentrations of susceptible drugs, potentially reducing efficacy. Some inhibitors act rapidly because they interfere directly with enzyme activity, whereas induction often requires synthesis of additional enzyme protein and therefore develops more gradually. Interactions can also occur through intestinal enzymes and transporters.
The clinical importance depends on the therapeutic window, magnitude of exposure change and susceptibility of the patient. A metabolic interaction may be beneficial in some circumstances, but unintended interactions can be clinically dangerous. Pharmacological management may involve avoiding combinations, adjusting doses or selecting alternative medicines. Accurate prediction of interactions requires knowledge of enzyme pathways, transporter systems, exposure relationships and the specific characteristics of the interacting drugs.
Genetic variation can produce major differences in Drug Metabolism between individuals. Polymorphisms in genes encoding metabolic enzymes can produce phenotypes associated with unusually rapid, intermediate, normal or slow metabolism for particular substrates. CYP2D6 provides a well studied example because genetic variation can substantially alter metabolism of numerous medicines. CYP2C19 and CYP2C9 also show clinically relevant genetic variability for selected drugs.
Pharmacogenetic consequences depend on the specific drug because increased metabolism can either reduce efficacy by lowering exposure to an active drug or increase activation of a prodrug. Genetics can also interact with environmental factors and other medicines, meaning that a genetically predicted metabolic phenotype may be modified by enzyme inhibition or induction. Pharmacogenomics therefore provides a framework for understanding interindividual variability but does not explain all differences in drug response.
Drug metabolism can produce active metabolites, inactive metabolites or toxic metabolites. Active metabolites may contribute substantially to the therapeutic effect and can prolong the overall pharmacological action even when the parent compound has been cleared. Some prodrugs depend deliberately on metabolic activation, meaning that inadequate conversion can reduce therapeutic efficacy. Toxic metabolites can cause organ injury if their formation exceeds detoxification and elimination capacity.
A classic mechanistic pattern involves formation of a reactive intermediate followed by detoxification through conjugation or other pathways. If protective systems become overwhelmed, reactive species can bind cellular macromolecules and cause oxidative stress, mitochondrial dysfunction or other damage. Liver toxicity is particularly relevant because the liver is a major metabolic organ, although metabolites can affect many tissues. Drug metabolism must therefore be evaluated not simply by measuring disappearance of the parent drug but by identifying the metabolites formed and understanding their biological properties.
Drug metabolism is investigated using in vitro enzyme systems, cultured cells, human tissue preparations, animal studies and clinical pharmacokinetic measurements. Recombinant enzymes can identify which metabolic pathways contribute to clearance, while microsomal or hepatocyte systems can provide more integrated information. Metabolite identification can use analytical techniques such as liquid chromatography and mass spectrometry. Physiologically based pharmacokinetic models can integrate enzyme activity, organ blood flow, tissue distribution and other parameters to predict human exposure under different scenarios.
Metabolic studies are important during drug development because they help determine clearance mechanisms, interaction risks, metabolite safety and appropriate dosing. Drug metabolism is closely related to but distinct from drug excretion. Metabolism changes chemical structure, whereas excretion physically removes substances or metabolites from the body. Both processes contribute to overall clearance. Understanding their relationship is essential for predicting drug half life, accumulation during repeated dosing and differences in exposure among patients with altered liver or kidney function.
